11/29
03:39 pm
hind
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
07:46 am
hind
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program [Yahoo! Finance]
Low
Report
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program [Yahoo! Finance]
11/25
07:00 am
hind
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
Low
Report
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
11/24
01:56 pm
hind
Vyome (NASDAQ:HIND) is now covered by analysts at
Weiss Ratings. They set a "sell (e-)" rating on the stock.
Neutral
Report
Vyome (NASDAQ:HIND) is now covered by analysts at
Weiss Ratings. They set a "sell (e-)" rating on the stock.
11/18
07:46 am
hind
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing [Yahoo! Finance]
Low
Report
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing [Yahoo! Finance]
11/18
07:00 am
hind
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Medium
Report
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
11/4
09:04 am
hind
Vyome Holdings Announces Results of Annual Shareholder Meeting
Low
Report
Vyome Holdings Announces Results of Annual Shareholder Meeting
10/9
01:06 am
hind
Medium
Report
10/3
06:38 am
hind
Vyome (NASDAQ:HIND) was upgraded by analysts at Maxim Group to a "strong-buy" rating.
Low
Report
Vyome (NASDAQ:HIND) was upgraded by analysts at Maxim Group to a "strong-buy" rating.
10/2
10:05 am
hind
Vyome (NASDAQ:HIND) was upgraded by analysts at Citigroup Inc. to a "buy" rating.
Low
Report
Vyome (NASDAQ:HIND) was upgraded by analysts at Citigroup Inc. to a "buy" rating.
10/2
09:12 am
hind
Vyome (NASDAQ:HIND) was given a new $15.00 price target on by analysts at Maxim Group.
Medium
Report
Vyome (NASDAQ:HIND) was given a new $15.00 price target on by analysts at Maxim Group.
10/1
03:06 am
hind
Medium
Report
9/29
07:26 am
hind
Vyome Holdings Acquires MIT AI Spinout Oculo Health [Yahoo! Finance]
Medium
Report
Vyome Holdings Acquires MIT AI Spinout Oculo Health [Yahoo! Finance]
9/29
07:00 am
hind
Vyome Holdings Acquires MIT AI Spinout Oculo Health
Medium
Report
Vyome Holdings Acquires MIT AI Spinout Oculo Health
9/24
12:36 am
hind
Reshape Lifesciences (NASDAQ:HIND) was upgraded by analysts at
Wall Stre
Low
Report
Reshape Lifesciences (NASDAQ:HIND) was upgraded by analysts at
Wall Stre
9/17
07:00 am
hind
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
Medium
Report
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
9/9
08:40 am
hind
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies [Yahoo! Finance]
Medium
Report
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies [Yahoo! Finance]
9/9
08:30 am
hind
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
Low
Report
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies